Insider Trading disclosures for Aktis Oncology Inc
The latest disclosure was made by Dr. Akos Czibere, M.D.,PhD in Aktis Oncology Inc where a trade of 12,500
shares done at an average price of $5.0
was reported to US exchanges on Sept. 23, 2026.
Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company.
A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).
| Client Name |
Client Category |
Action |
Reported to Exchange |
Quantity |
Post Transaction Holding |
Traded % |
Avg. Price |
Value |
Security Type |
|
Dr. Akos Czibere, M.D.,PhD
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.95 per share. |
23 Sep 2026 |
12,500 |
12,500
|
-
|
5.0 |
61,875
|
- |
|
Dr. Akos Czibere, M.D.,PhD
|
Chief Medical Officer |
Sale of securities on an exchange or to another person at price $ 20.19 per share. |
23 Sep 2026 |
5,099 |
7,401
|
-
|
20.2 |
102,973
|
- |
|
Dr. Akos Czibere, M.D.,PhD
|
Chief Medical Officer |
Sale of securities on an exchange or to another person at price $ 21.03 per share. |
23 Sep 2026 |
7,401 |
0
|
-
|
21.0 |
155,648
|
- |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges